Sort   by:  
 Page size 
MetabolomicsTargeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2-) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves ...

2026-08-21 | MTBLS11671 | MetaboLights
MetabolomicsThe phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 inhibitor 3PO is a modulator of neutrophil metabolism, ROS production and NET release
Neutrophils are key effector leukocytes of the innate immune system and play a pivotal role in defending the host against microbial infections. Recent studies have identified a crucial link between glycolysis and neutrophil cellular functions. We have investigated in human neutrophils, the intricate...
2025-08-14 | MTBLS6215 | MetaboLights
MetabolomicsMetabolomics of human primary B-ALL cells treated by BCR-Abl1 inhibitor, STI571, and p190 BCR-Abl+ BAF3 cells with ASS1 knockdown
Analyze the Metabolomics changes in B-ALL cells after the treatment of imatinib and p190+ BAF3 cells with ASS1 knockdown or left untreated. two methods as the below LC-MS description showed were used.
2026-07-08 | MTBLS14638 | MetaboLights
ProteomicsInvestigation of interaction of p97, p37, PPI, SDS22 and Inhibitor-3 using cross-linking mass spectrometry (CL-MS)
In this project we investigated the complexes PPI/SDS22/Inhibitor-3 and p97/p37/PPI/SDS22/Inhibitor-3 by CL-MS using DSBU as crosslinker.
ORGANISM(S): Homo sapiens (Human) 
2024-11-22 | PXD026696 | Pride
Dsbu Ppi Inhibitor-3 Sds22 P97 
GenomicsTranscriptome-wide effect profile of HuR inhibitor KH-3
Transcriptome-wide effect profile of HuR inhibitor KH-3
PRJNA531021 | ENA
TranscriptomicsGSK-3 inhibitor treatment effect on MLL leukemia cell
Human leukemia cell line RS4.11 was treated with GSK-3 inhibitor SB216763 for 20 hours. Gene expression profiling was performed to analyze genes affected by GSK-3 inhibition. Human leukemia cell line RS4.11 was grown in vitro and treated with 10 uM GSK-3 inhibitor SB216763 or solvent DMSO for 20 h...
ORGANISM(S): Homo sapiens 
2010-05-27 | E-GEOD-19736 | biostudies-arrayexpress
TranscriptomicsGene expression changes upon treatment of T47D breast cancer cells with the Pan-PI3 kinase inhibitor GDC-0941
We sought to determine genes whose expression changed upon treatment with a selective inhibitor of class I PI3 kinase. Total of 6 samples: cells were treated with GDC-0941 at a concentration of 1mM for 6 hours (3 replicates) and control (3 replicates)
ORGANISM(S): Homo sapiens 
2010-06-08 | E-GEOD-20719 | biostudies-arrayexpress
TranscriptomicsRho transcription inhibitor CCG-1423 effect on PC-3 cells
Analysis of serum starved PC-3 cells treated with CCG-1423, Latrunculin B, or the transcription elongation inhibitor DRB for 2 or 24 hours. Results provide insights to potential therapeutic approaches to cancer metastasis. Twenty one samples in triplicate were analyzed and compared to the DMSO-treat...
ORGANISM(S): Homo sapiens 
2013-05-01 | E-GEOD-30188 | biostudies-arrayexpress
TranscriptomicsGSK-3 inhibitor treatment effect on MLL leukemia cell
Human leukemia cell line RS4.11 was treated with GSK-3 inhibitor SB216763 for 20 hours. Gene expression profiling was performed to analyze genes affected by GSK-3 inhibition.
ORGANISM(S): Homo sapiens 
2010-05-01 | GSE19736 | GEO
Genomics3' sequencing of nuclear and cytoplasmic fractions following treatment with a CLK inhibitor
3' sequencing of nuclear and cytoplasmic fractions following treatment with a CLK inhibitor
PRJEB65860 | ENA
Sort   by:  
 Page size